Standard
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks : pooled analysis of two Scandinavian trials. / Dalgard, O.; Bjoro, K.; Larsen, Helmer Ring; Verbaan, H.
In:
European Journal of Gastroenterology and Hepatology, Vol. 22, No. 5, 01.05.2010, p. 552-556.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Dalgard, O, Bjoro, K, Larsen, HR & Verbaan, H 2010, 'In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials', European Journal of Gastroenterology and Hepatology, vol. 22, no. 5, pp. 552-556.
APA
Dalgard, O., Bjoro, K., Larsen, H. R., & Verbaan, H. (2010). In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepatology, 22(5), 552-556.
Vancouver
Dalgard O, Bjoro K, Larsen HR, Verbaan H. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepatology. 2010 May 1;22(5):552-556.
Author
Dalgard, O. ; Bjoro, K. ; Larsen, Helmer Ring ; Verbaan, H. / In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks : pooled analysis of two Scandinavian trials. In: European Journal of Gastroenterology and Hepatology. 2010 ; Vol. 22, No. 5. pp. 552-556.
Bibtex
@article{8c3ff6e8fb5549e0a5758d1ec32e1965,
title = "In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "O. Dalgard and K. Bjoro and Larsen, {Helmer Ring} and H. Verbaan",
year = "2010",
month = may,
day = "1",
language = "English",
volume = "22",
pages = "552--556",
journal = "European Journal of Gastroenterology and Hepatology, Supplement",
issn = "0954-691X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "5",
}
RIS
TY - JOUR
T1 - In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks
T2 - pooled analysis of two Scandinavian trials
AU - Dalgard, O.
AU - Bjoro, K.
AU - Larsen, Helmer Ring
AU - Verbaan, H.
PY - 2010/5/1
Y1 - 2010/5/1
KW - Former Faculty of Pharmaceutical Sciences
M3 - Journal article
VL - 22
SP - 552
EP - 556
JO - European Journal of Gastroenterology and Hepatology, Supplement
JF - European Journal of Gastroenterology and Hepatology, Supplement
SN - 0954-691X
IS - 5
ER -
